Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 12/2017

01-12-2017 | Review Article

Bariatric Surgery Resistance: Using Preoperative Lifestyle Medicine and/or Pharmacology for Metabolic Responsiveness

Authors: Nicole M. Gilbertson, Andrew S. Paisley, Sibylle Kranz, Arthur Weltman, Jennifer L. Kirby, Peter T. Hallowell, Steven K. Malin

Published in: Obesity Surgery | Issue 12/2017

Login to get access

Abstract

Bariatric surgery is an effective and durable treatment for individuals with obesity and its associated comorbidities. However, not all patients meet weight loss and/or cardiometabolic goals following bariatric surgery, suggesting that some people are bariatric surgery resistant. The reason for this resistance is unclear, but potential factors, such as adiposity-derived inflammation, insulin resistance, hyperglycemia, and aerobic fitness prior to surgery, have been related to blunted surgery responsiveness. Exercise, diet, and/or pharmacology are effective at reducing inflammation and improving insulin action as well as physical function. Herein, we present data that supports the novel hypothesis that intervening prior to surgery can enhance disease resolution in people who are resistant to bariatric surgery.
Literature
1.
2.
McPhee JB, Schertzer JD. Immunometabolism of obesity and diabetes: microbiota link compartmentalized immunity in the gut to metabolic tissue inflammation. Clin Sci. 2015;129(12):1083–96.PubMedCrossRef
3.
Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17(1):4–12.PubMed
4.
5.
Finkelstein EA, Trogdon JG, Cohen JW, et al. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff. 2009;28(5):822–31.CrossRef
6.
7.
Barte JC, ter Bogt NC, Bogers RP, et al. Maintenance of weight loss after lifestyle interventions for overweight and obesity, a systematic review. Obes Rev. 2010;11(12):899–906.PubMedCrossRef
8.
Malin SK, Braun B. Impact of metformin on exercise-induced metabolic adaptations to lower type 2 diabetes risk. Exerc Sport Sci Rev. 2016;44(1):4–11.PubMedCrossRef
9.
Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.PubMedCrossRef
10.
Solomon TP, Thyfault JP. Type 2 diabetes sits in a chair. Diabetes Obes Metab. 2013;15(11):987–92.PubMedCrossRef
11.
Li JF, Lai DD, Lin ZH, et al. Comparison of the long-term results of Roux-en-Y gastric bypass and sleeve gastrectomy for morbid obesity: a systematic review and meta-analysis of randomized and nonrandomized trials. Surg Laparosc Endosc Percutan Tech. 2014;24(1):1–11.PubMedCrossRef
12.
Robinson AH, Adler S, Stevens HB, et al. What variables are associated with successful weight loss outcomes for bariatric surgery after 1 year? Surg Obes Relat Dis. 2014;10(4):697–704.PubMedPubMedCentralCrossRef
13.
Malin SK, Solomon TP, Blaszczak A, et al. Pancreatic beta-cell function increases in a linear dose-response manner following exercise training in adults with prediabetes. Am J Physiol Endocrinol Metab. 2013;305(10):E1248–54.PubMedPubMedCentralCrossRef
14.
Peluso L, Vanek VW. Efficacy of gastric bypass in the treatment of obesity-related comorbidities. Nutr Clin Pract. 2007;22(1):22–8.PubMedCrossRef
15.
16.
Ma Y, Pagoto SL, Olendzki BC, et al. Predictors of weight status following laparoscopic gastric bypass. Obes Surg. 2006;16(9):1227–31.PubMedCrossRef
17.
Hatoum IJ, Stein HK, Merrifield BF, et al. Capacity for physical activity predicts weight loss after Roux-en-Y gastric bypass. Obesity (Silver Spring). 2009;17(1):92–9.CrossRef
18.
19.
Livingston EH, Huerta S, Arthur D, et al. Male gender is a predictor of morbidity and age a predictor of mortality for patients undergoing gastric bypass surgery. Ann Surg. 2002;236(5):576–82.PubMedPubMedCentralCrossRef
20.
Cleasby ME, Jamieson PM, Atherton PJ. Insulin resistance and sarcopenia: mechanistic links between common co-morbidities. J Endocrinol. 2016;229(2):67–81.CrossRef
21.
22.
Hagobian TA, Evero N. Exercise and weight loss: what is the evidence of sex differences? Curr Obes Rep. 2013;2(1):86–92.CrossRef
23.
Ding EL, Song Y, Malik VS, et al. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2006;295(11):1288–99.PubMedCrossRef
24.
Hellstrom L, Wahrenberg H, Hruska K, et al. Mechanisms behind gender differences in circulating leptin levels. J Intern Med. 2000;247(4):457–62.PubMedCrossRef
25.
Kennedy A, Gettys TW, Watson P, et al. The metabolic significance of leptin in humans: gender-based differences in relationship to adiposity, insulin sensitivity, and energy expenditure. J Clin Endocrinol Metab. 1997;82(4):1293–300.PubMed
26.
Mantzoros CS. The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med. 1999;130(8):671–80.PubMedCrossRef
27.
Faerch K, Borch-Johnsen K, Vaag A, et al. Sex differences in glucose levels: a consequence of physiology or methodological convenience? The Inter99 study. Diabetologia. 2010;53(5):858–65.PubMedCrossRef
28.
Makovey J, Naganathan V, Seibel M, et al. Gender differences in plasma ghrelin and its relations to body composition and bone—an opposite-sex twin study. Clin Endocrinol. 2007;66(4):530–7.
29.
Purnell JQ, Weigle DS, Breen P, et al. Ghrelin levels correlate with insulin levels, insulin resistance, and high-density lipoprotein cholesterol, but not with gender, menopausal status, or cortisol levels in humans. J Clin Endocrinol Metab. 2003;88(12):5747–52.PubMedCrossRef
30.
Anderson WA, Greene GW, Forse RA, et al. Weight loss and health outcomes in African Americans and whites after gastric bypass surgery. Obesity. 2007;15(6):1455–63.PubMedCrossRef
31.
Parikh M, Lo H, Chang C, et al. Comparison of outcomes after laparoscopic adjustable gastric banding in African-Americans and whites. Surg Obes Relat Dis. 2006;2(6):607–12.PubMedCrossRef
32.
Cossrow N, Falkner B. Race/ethnic issues in obesity and obesity-related comorbidities. J Clin Endocrinol Metab. 2004;89(6):2590–4.PubMedCrossRef
33.
Olson NC, Callas PW, Hanley AJ, et al. Circulating levels of TNF-alpha are associated with impaired glucose tolerance, increased insulin resistance, and ethnicity: the Insulin Resistance Atherosclerosis Study. J Clin Endocrinol Metab. 2012;97(3):1032–40.PubMedPubMedCentralCrossRef
34.
Kern PA, Ranganathan S, Li C, et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001;280(5):745–51.
35.
Lindquist CH, Gower BA, Goran MI. Role of dietary factors in ethnic differences in early risk of cardiovascular disease and type 2 diabetes. Am J Clin Nutr. 2000;71(3):725–32.PubMed
36.
Conjeevaram HS, Kleiner DE, Everhart JE, et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology. 2007;45(1):80–7.PubMedCrossRef
37.
Gullick AA, Graham LA, Richman J, et al. Association of race and socioeconomic status with outcomes following laparoscopic Roux-en-Y gastric bypass. Obes Surg. 2015;25(4):705–11.PubMedCrossRef
38.
Lutfi R, Torquati A, Sekhar N, et al. Predictors of success after laparoscopic gastric bypass: a multivariate analysis of socioeconomic factors. Surg Endosc. 2006;20(6):864–7.PubMedCrossRef
39.
Kinzl JF, Schrattenecker M, Traweger C, et al. Psychosocial predictors of weight loss after bariatric surgery. Obes Surg. 2006;16(12):1609–14.PubMedCrossRef
40.
van Hout GC, Verschure SK, van Heck GL. Psychosocial predictors of success following bariatric surgery. Obes Surg. 2005;15(4):552–60.PubMedCrossRef
41.
Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112(12):1821–30.PubMedPubMedCentralCrossRef
42.
Brethauer SA, Heneghan HM, Eldar S, et al. Early effects of gastric bypass on endothelial function, inflammation, and cardiovascular risk in obese patients. Surg Endosc. 2011;25(8):2650–9.PubMedCrossRef
43.
Madsen EL, Rissanen A, Bruun JM, et al. Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study. Eur J Endocrinol. 2008;158(2):179–87.PubMedCrossRef
44.
Heneghan HM, Huang H, Kashyap SR, et al. Reduced cardiovascular risk after bariatric surgery is linked to plasma ceramides, apolipoprotein-B100, and ApoB100/A1 ratio. Surg Obes Relat Dis. 2013;9(1):100–7.PubMedCrossRef
45.
Malin SK, Bena J, Abood B, et al. Attenuated improvements in adiponectin and fat loss characterize type 2 diabetes non-remission status after bariatric surgery. Diabetes Obes Metab. 2014;16(12):1230–8.PubMedPubMedCentralCrossRef
46.
Hirsch FF, Pareja JC, Geloneze SR, et al. Comparison of metabolic effects of surgical-induced massive weight loss in patients with long-term remission versus non-remission of type 2 diabetes. Obes Surg. 2012;22(6):910–7.PubMedCrossRef
47.
Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86(5):1930–5.PubMedCrossRef
48.
Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. 1999. Biochem Biophys Res Commun. 2012;425(3):560–4.PubMedCrossRef
49.
Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab. 2001;86(8):3815–9.PubMedCrossRef
50.
Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383(9922):1068–83.PubMedCrossRef
51.
Gavin TP, Ernst JM, Caudill SE, et al. Insulin sensitivity is related to glycemic control in type 2 diabetes and diabetes remission after Roux-en Y gastric bypass. Surgery. 2014;155(6):1036–43.PubMedCrossRef
52.
53.
Torquati A, Lutfi R, Abumrad N, et al. Roux-en-Y gastric bypass surgery the most effective treatment for type 2 diabetes mellitus in morbidly obese patients? J Gastrointest Surg. 2005;9(8):1112–8.PubMedCrossRef
54.
Hall TC, Pellen MG, Sedman PC, et al. Preoperative factors predicting remission of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery for obesity. Obes Surg. 2010;20(9):1245–50.PubMedCrossRef
55.
Wang GF, Yan YX, Xu N, et al. Predictive factors of type 2 diabetes mellitus remission following bariatric surgery: a meta-analysis. Obes Surg. 2015;25(2):199–208.PubMedCrossRef
56.
Mehaffey JH, Mullen MG, Mehaffey RL, et al. Type 2 diabetes remission following gastric bypass: does DiaRem stand the test of time? Surg Endosc. 2017;31(2):538–42.
57.
Khanna V, Malin SK, Bena J, et al. Adults with long-duration type 2 diabetes have blunted glycemic and beta-cell function improvements after bariatric surgery. Obesity (Silver Spring). 2015;23(3):523–6.CrossRef
58.
Nguyen NQ, Game P, Bessell J, et al. Outcomes of Roux-en-Y gastric bypass and laparoscopic adjustable gastric banding. World J Gastroenterol. 2013;19(36):6035–43.PubMedPubMedCentralCrossRef
59.
60.
Fernandez AZ, DeMaria EJ, Tichansky DS, et al. Experience with over 3,000 open and laparoscopic bariatric procedures: multivariate analysis of factors related to leak and resultant mortality. Surg Endosc. 2004;18(2):193–7.PubMedCrossRef
61.
Longitudinal Assessment of Bariatric Surgery (LABS) Consortium, Flum DR, Belle SH, et al. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med. 2009;361(5):445–54.CrossRef
62.
Jacobi D, Ciangura C, Couet C, et al. Physical activity and weight loss following bariatric surgery. Obes Rev. 2011;12(5):366–77.PubMedCrossRef
63.
McCullough PA, Gallagher MJ, Dejong AT, et al. Cardiorespiratory fitness and short-term complications after bariatric surgery. Chest. 2006;130(2):517–25.PubMedCrossRef
64.
Bond DS, Jakicic JM, Unick JL, et al. Pre- to postoperative physical activity changes in bariatric surgery patients: self report vs. objective measures. Obesity. 2010;18(12):2395–7.PubMedPubMedCentralCrossRef
65.
Trivax JE, Gallagher MJ, Alexander DV, et al. Poor aerobic fitness predicts complications associated with bariatric surgery. Chest. 2005;128(4)
66.
Berglind D, Willmer M, Eriksson U, et al. Longitudinal assessment of physical activity in women undergoing Roux-en-Y gastric bypass. Obes Surg. 2015;25(1):119–25.PubMedCrossRef
67.
Baillot A, Mampuya WM, Comeau E, et al. Feasibility and impacts of supervised exercise training in subjects with obesity awaiting bariatric surgery: a pilot study. Obes Surg. 2013;23(7):882–91.PubMedCrossRef
68.
Baillot A, Mampuya WM, Dionne IJ, et al. Impacts of supervised exercise training in addition to interdisciplinary lifestyle management in subjects awaiting bariatric surgery: a randomized controlled study. Obes Surg. 2016;26(11):2602–10.
69.
Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343–50.PubMedCrossRef
70.
Henriksen EJ. Invited review: effects of acute exercise and exercise training on insulin resistance. J Appl Physiol. 2002;93(2):788–96.PubMedCrossRef
71.
Hawley JA. Exercise as a therapeutic intervention for the prevention and treatment of insulin resistance. Diabetes Metab Res Rev. 2004;20(5):383–93.PubMedCrossRef
72.
Mathur N, Pedersen BK. Exercise as a mean to control low-grade systemic inflammation. Mediators Inflamm. 2008;2008:6.
73.
Hopps E, Canino B, Caimi G. Effects of exercise on inflammation markers in type 2 diabetic subjects. Acta Diabetol. 2011;48(3):183–9.PubMedCrossRef
74.
Shah M, Snell PG, Rao S, et al. High-volume exercise program in obese bariatric surgery patients: a randomized, controlled trial. Obesity. 2011;19(9):1826–34.PubMedCrossRef
75.
Coen PM, Tanner CJ, Helbling NL, et al. Clinical trial demonstrates exercise following bariatric surgery improves insulin sensitivity. J Clin Invest. 2015;125(1):248–57.PubMedCrossRef
76.
Coen PM, Menshikova EV, Distefano G, et al. Exercise and weight loss improve muscle mitochondrial respiration, lipid partitioning, and insulin sensitivity after gastric bypass surgery. Diabetes. 2015;64(11):3737–50.PubMedPubMedCentralCrossRef
77.
Stegen S, Derave W, Calders P, et al. Physical fitness in morbidly obese patients: effect of gastric bypass surgery and exercise training. Obes Surg. 2011;21(1):61–70.PubMedCrossRef
78.
Dube JJ, Allison KF, Rousson V, et al. Exercise dose and insulin sensitivity: relevance for diabetes prevention. Med Sci Sports Exerc. 2012;44(5):793–9.PubMedPubMedCentralCrossRef
79.
Houmard JA, Tanner CJ, Slentz CA, et al. Effect of the volume and intensity of exercise training on insulin sensitivity. J Appl Physiol. 2004;96(1):101–6.PubMedCrossRef
80.
Hamer M, Stamatakis E. Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. J Clin Endocrinol Metab. 2012;97(7):2482–8.PubMedPubMedCentralCrossRef
81.
82.
Baldry EL, Leeder PC, Idris IR. Pre-operative dietary restriction for patients undergoing bariatric surgery in the UK: observational study of current practice and dietary effects. Obes Surg. 2014;24(3):416–21.PubMedCrossRef
83.
Livhits M, Mercado C, Yermilov I, et al. Preoperative predictors of weight loss following bariatric surgery: systematic review. Obes Surg. 2012;22(1):70–89.PubMedCrossRef
84.
Alami RS, Morton JM, Schuster R, et al. Is there a benefit to preoperative weight loss in gastric bypass patients? A prospective randomized trial. Surg Obes Relat Dis. 2007;3(2):141–6.PubMedCrossRef
85.
Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009;360(9):859–73.PubMedPubMedCentralCrossRef
86.
Van Nieuwenhove Y, Dambrauskas Z, Campillo-Soto A, et al. Preoperative very low-calorie diet and operative outcome after laparoscopic gastric bypass: a randomized multicenter study. Arch Surg. 2011;146(11):1300–5.PubMedCrossRef
87.
Huerta S, Dredar S, Hayden E, et al. Preoperative weight loss decreases the operative time of gastric bypass at a Veterans Administration hospital. Obes Surg. 2008;18(5):508–12.PubMedCrossRef
88.
Martin LF, Tan TL, Holmes PA, et al. Can morbidly obese patients safely lose weight preoperatively? Am J Surg. 1995;169(2):245–53.PubMedCrossRef
89.
Pournaras D, Nygren J, Hagstrom-Toft E, et al. Improved glucose metabolism after gastric bypass: evolution of the paradigm. Surg Obes Relat Dis. 2016;12:1457–65.PubMedCrossRef
90.
Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol. 2006;45(4):600–6.PubMedCrossRef
91.
Nguyen NT, Longoria M, Gelfand DV, et al. Staged laparoscopic Roux-en-Y: a novel two-stage bariatric operation as an alternative in the super-obese with massively enlarged liver. Obes Surg. 2005;15(7):1077–81.PubMedCrossRef
92.
van Wissen J, Bakker N, Doodeman HJ, et al. Preoperative methods to reduce liver volume in bariatric surgery: a systematic review. Obes Surg. 2016;26(2):251–6.PubMedCrossRef
93.
94.
Edholm D, Kullberg J, Haenni A, et al. Preoperative 4-week low-calorie diet reduces liver volume and intrahepatic fat, and facilitates laparoscopic gastric bypass in morbidly obese. Obes Surg. 2011;21(3):345–50.PubMedCrossRef
95.
Brody F, Vaziri K, Garey C, et al. Preoperative liver reduction utilizing a novel nutritional supplement. J Laparoendosc Adv Surg Tech A. 2011;21(6):491–5.PubMedCrossRef
96.
Colles SL, Dixon JB, Marks P, et al. Preoperative weight loss with a very-low-energy diet: quantitation of changes in liver and abdominal fat by serial imaging. Am J Clin Nutr. 2006;84(2):304–11.PubMed
97.
Alvarado R, Alami RS, Hsu G, et al. The impact of preoperative weight loss in patients undergoing laparoscopic Roux-en-Y gastric bypass. Obes Surg. 2005;15(9):1282–6.PubMedCrossRef
98.
Dagogo-Jack S, Alberti GM. Management of diabetes mellitus in surgical patients. Diabetes Spectrum. 2002;15(1):44–8.CrossRef
99.
Gonzalez-Perez J, Sanchez-Leenheer S, Delgado AR, et al. Clinical impact of a 6-week preoperative very low calorie diet on body weight and liver size in morbidly obese patients. Obes Surg. 2013;23(10):1624–31.PubMedCrossRef
100.
Rector RS, Warner SO, Liu Y, et al. Exercise and diet induced weight loss improves measures of oxidative stress and insulin sensitivity in adults with characteristics of the metabolic syndrome. Am J Physiol Endocrinol Metab. 2007;293(2):500–6.CrossRef
101.
Coen PM, Goodpaster BH. A role for exercise after bariatric surgery?. Diabetes Obes Metab 2016;18(1):16–23.
102.
Dodson RM, Firoozmand A, Hyder O, et al. Impact of sarcopenia on outcomes following intra-arterial therapy of hepatic malignancies. J Gastrointest Surg. 2013;17(12):2123–32.PubMedPubMedCentralCrossRef
103.
Psutka SP, Carrasco A, Schmit GD, et al. Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. Cancer 2014;120(18):2910–18.
104.
105.
Kalyani RR, Corriere M, Ferrucci L. Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases. Lancet Diabetes Endocrinol. 2014;2(10):819–29.PubMedPubMedCentralCrossRef
106.
Ross R, Pedwell H, Rissanen J. Effects of energy restriction and exercise on skeletal muscle and adipose tissue in women as measured by magnetic resonance imaging. Am J Clin Nutr. 1995;61(6):1179–85.PubMed
107.
Pan DA, Lillioja S, Kriketos AD, et al. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes. 1997;46(6):983–8.PubMedCrossRef
108.
Yokoyama H, Emoto M, Araki T, et al. Effect of aerobic exercise on plasma adiponectin levels and insulin resistance in type 2 diabetes. Diabetes Care. 2004;27(7):1756–8.PubMedCrossRef
109.
Haus JM, Solomon TP, Marchetti CM, et al. Free fatty acid-induced hepatic insulin resistance is attenuated following lifestyle intervention in obese individuals with impaired glucose tolerance. J Clin Endocrinol Metab. 2010;95(1):323–7.PubMedCrossRef
110.
Tamura Y, Tanaka Y, Sato F, et al. Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2005;90(6):3191–6.PubMedCrossRef
111.
Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–61.PubMedCrossRef
112.
Scheen AJ, Van Gaal LF. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2(11):911–22.PubMedCrossRef
113.
Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297–308.PubMedCrossRef
114.
Garvey WT, Ryan DH, Henry R, et al. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. Diabetes Care. 2014;37(4):912–21.PubMedPubMedCentralCrossRef
115.
Martin CK, Redman LM, Zhang J, et al. Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. J Clin Endocrinol Metab. 2011;96(3):837–45.PubMedCrossRef
116.
O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity. 2012;20(7):1426–36.PubMedCrossRef
117.
Smith SR, Fujioka K, Gupta AK, et al. Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity. Diabetes Obes Metab. 2013;15(9):863–6.PubMedCrossRef
118.
Hollander P, Gupta AK, Plodkowski R, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022–9.PubMedPubMedCentralCrossRef
119.
Holst JJ, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol. 2009;297(1–2):127–36.PubMedCrossRef
120.
Wood GC, Gerhard GS, Benotti P, et al. Preoperative use of incretins is associated with increased diabetes remission after RYGB surgery among patients taking insulin: a retrospective cohort analysis. Ann Surg. 2015;261(1):125–8.PubMedPubMedCentralCrossRef
121.
Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes Randomized Clinical Trial. JAMA. 2015;314(7):687–99.PubMedCrossRef
122.
Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes. 2013;37(11):1443–51.CrossRef
123.
Rhee MK, Herrick K, Ziemer DC, et al. Many Americans have pre-diabetes and should be considered for metformin therapy. Diabetes Care. 2010;33(1):49–54.PubMedCrossRef
124.
DeFronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–95.PubMedPubMedCentralCrossRef
125.
Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004;27(1):256–63.PubMedCrossRef
126.
Chaggar PS, Shaw SM, Williams SG. Review article: thiazolidinediones and heart failure. Diab Vasc Dis Res. 2009;6(3):146–52.PubMedCrossRef
127.
Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR, et al. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf. 2009;32(3):187–202.PubMedCrossRef
128.
Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427–43.PubMedCrossRef
129.
Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–89.PubMedCrossRef
130.
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.PubMedCrossRef
131.
Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154(9):602–13.PubMedPubMedCentralCrossRef
132.
133.
Pi-Sunyer X, Blackburn G, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007;30(6):1374–83.PubMedCrossRef
134.
Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683–93.PubMedCrossRef
135.
McGrice M, Don Paul K. Interventions to improve long-term weight loss in patients following bariatric surgery: challenges and solutions. Diabetes Metab Syndr Obes. 2015;8:263–74.PubMedPubMedCentralCrossRef
136.
Stein J, Stier C, Raab H, et al. Review article: the nutritional and pharmacological consequences of obesity surgery. Aliment Pharmacol Ther. 2014;40(6):582–609.PubMedCrossRef
Metadata
Title
Bariatric Surgery Resistance: Using Preoperative Lifestyle Medicine and/or Pharmacology for Metabolic Responsiveness
Authors
Nicole M. Gilbertson
Andrew S. Paisley
Sibylle Kranz
Arthur Weltman
Jennifer L. Kirby
Peter T. Hallowell
Steven K. Malin
Publication date
01-12-2017
Publisher
Springer US
Published in
Obesity Surgery / Issue 12/2017
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-017-2966-1

Other articles of this Issue 12/2017

Obesity Surgery 12/2017 Go to the issue

Video Submission

Totally Robotic Combined Roux-en-Y Gastric Bypass and Hiatal Hernia Repair with Biological Mesh: Technical Points

Original Contributions

Changes in Dietary Intake and Eating Behavior in Adolescents After Bariatric Surgery: an Ancillary Study to the Teen-LABS Consortium

Original Contributions

Reflux, Sleeve Dilation, and Barrett’s Esophagus after Laparoscopic Sleeve Gastrectomy: Long-Term Follow-Up

Original Contributions

Early Effects of Sleeve Gastrectomy on Obesity-Related Cytokines and Bile Acid Metabolism in Morbidly Obese Japanese Patients

Original Contributions

Bariatric Surgery in Septuagenarians: a Comparison with <60 Year Olds

Brief Communication

Glucose Variability After Bariatric Surgery: Is Prediction of Diabetes Remission Possible?